

# @SIP\_PainPolicy @EU\_Health @eHealth\_EU



#### WELCOME!

How can digitalising health services reduce the societal impact of pain?



The 'Societal Impact of Pain' (SIP) platform is a multi-stakeholder partnership led by the European Pain Federation EFIC and Pain Alliance Europe (PAE), which aims to raise awareness of pain and change pain policies. The scientific framework of the SIP platform is under the responsibility of EFIC and the strategic direction of the project is defined by both partners. The pharmaceutical company Grünenthal GmbH is the main sponsor of the Societal Impact of Pain (SIP) platform.



### **Patrice FORGET**

Chair of the Societal Impact of Pain (SIP)

# **Deirdre RYAN** President, Pain Alliance Europe (PAE)



14h00-14h05: Welcome and introduction

# STATE OF THE ART: DIGITAL HEALTH, PAIN ASSESSMENT, AND QUALITY INDICATORS

# **Esther POGATZKI-ZAHN**

European Pain Federation (EFIC), Department of Anaesthesiology & Intensive Care, University of Münster





# IMI-PainCare and Patient Reported Outcomes (PRO) uptake by the European Medicines Agency (EMA) Univ.-Prof. Dr. med. Esther Pogatzki-Zahn

Department of Anesthesiology, Intensive Care and Pain Medicine University Hospital Muenster

### Conflicts of Interest declaration: Esther Pogatzki-Zahn

Part of the present presentation relates to results obtained in the Project IMI-PainCare. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No [777500]. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

The statements and opinions presented here reflect the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

etpia





www.imi.europa.eu

During the last 5 years, EPZ received received advisory board and lecture fees from Grünenthal GmbH, MSD Sharp & DOHME GmbH, Mundipharma GmbH; Mundipharma International; Janssen-Cilag GmbH; Fresenius Kabi, TAD and AceIRx and from Mundipharma GmbH and Grunenthal for research activities.

EPZ currently receives scientific support from the DFG (currently: PO1319/3-1; PO1319/4-1; PO1319/5-); the BMBF, ERANet LAC (IDN17009), and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777500 (IMI Pain Care, PI of WP2).

EPZ is board/council member and/or vice chair/chair of several national and international pain and anaesthesia societies and committees including the International Association for the Study of Pain (IASP), Acute Pain SIG of the IASP; European Society Anesthesiology (ESA, past chair of the subcommittee Acute and Chronic Pain and Palliative Medicine Pain Management; member of the research committee), German Society of Pain (German Chapter of IASP), German Society of Anaesthesiology (DGAI, Pain subcommittee) and the Sertürner Society;

EPZ is Deputy Editor - in - Chief of the EJA

# Patient – Reported – Outcomes (PRO) – it is the patients view that matters



https://silverlinecrm.com/blog/healthcare/provider/5reasons-patient-360-matters/

#### **Outcome Assessment in Pain Studies (Postsurgical Pain)**

Systematic Review and Meta-Analysis

#### PAIN

#### Assessing outcome in postoperative pain trials: are we missing the point? A systematic review of painrelated outcome domains reported in studies early after total knee arthroplasty

Stephan Bigalke<sup>a,b</sup>, Timo V. Maeßen<sup>a</sup>, Kathrin Schnabel<sup>a</sup>, Ulrike Kaiser<sup>c</sup>, Daniel Segelcke<sup>a</sup>, Christine H. Meyer-Frießem<sup>b</sup>, Hiltrud Liedgens<sup>d</sup>, Philipp A. Macháček<sup>e</sup>, Peter K. Zahn<sup>b</sup>, Esther M. Pogatzki-Zahn<sup>a,\*</sup>





#### Consensus of PROs to be assessed in clinical trials after surgery



Panel member: 9 stakeholder groups:

Anesthesiologists Pain Specialists IMI Group (clinical) surgeons clinical psychologists physiotherapists HTA/PRO experts and Regulatory experts Pain Nurses IMI-EFFPIA (pharmacists) Patient representatives 4 participants / group



EU/IMI Horizon 2020Grant #777500



Pogatzki-Zahn et al, PAIN 2021;162(11):2717-2736.



Panel member: 9 stakeholder groups:

Anesthesiologists Pain Specialists IMI Group (clinical) surgeons clinical psychologists physiotherapists HTA/PRO experts and Regulatory experts Pain Nurses IMI-EFFPIA (pharmacists) Patient representatives 4 participants / group





EU/IMI Horizon 2020Grant #777500

Goal: Consensus on measurements for each outcome domain best suited for assessment of pain-related outcome early after surgery

| Table 2. Examples of existing core outcome set recommendations for patient-reported outcome in chronic pain conditions |   |   |  |  |  |  |  |
|--|---|---|--|--|--|--|--|
| Name of initiative<br>References   | Condition<br>Intervention<br>Scope of application<br>Location   | Core outcome<br>set – domains   | Core outcome<br>set – measurement instruments  | Involvement of patients                          |  |  |  |
| IMMPACT<br>[24,25]   | Chronic pain<br>No specific<br>Clinical trials<br>International   | Pain<br>Physical functioning<br>Emotional functioning<br>Participant's ratings of global<br>improvement<br>Symptoms and adverse events, and<br>Participant's disposition  | 11 Point (0–10) numerical rating scale<br>of pain intensity<br>Usage of rescue analgesics<br>Categorical rating of pain intensity<br>(none, mild, moderate, severe) in<br>circumstances in which numerical<br>ratings may be problematic<br>Multidimensional Pain Inventory<br>Interference Scale or<br>Brief pain inventory interference items<br>Beck depression inventory or<br>Profile of mood states<br>Patient global assessment of change<br>Passive capture of spontaneously<br>reported adverse events and<br>symptoms and use of open-ended<br>prompts<br>Detailed information regarding<br>participant recruitment and progress<br>through the trial, including all<br>information specified in the<br>CONSORT guidelines | Not for domain and<br>measurement<br>instruments |  |  |  |
| Low back pain<br>[26,27]   | Nonspecific low back pain<br>No specific<br>Clinical trials<br>International  | Physical functioning<br>Pain intensity<br>Health-related quality of life<br>Number of deaths  | Oswestry Disability Index version 2.1;<br>24-item Roland Morris Disability<br>Questionnaire<br>NRS (0 no pain/10 worst pain) in a<br>week recall period for average pain<br>Short form health survey 12; 10.item<br>PROMIS Global Health<br>Number of deaths   | Yes  |  |  |  |
| VAPAIN<br>[31]   | Chronic pain<br>Interdisciplinary multimodal pain therapy<br>Effectiveness studies and daily record<br>keeping<br>International | Pain intensity<br>Pain frequency<br>Emotional wellbeing<br>Physical activity<br>Satisfaction with social roles and<br>activities<br>Productivity (including absenteeism and<br>presentism)<br>Patient perception of treatment goal<br>achievement<br>Health-related auality of life | In preparation   | Yes  |  |  |  |
| Fibromyalgia/<br>OMERACT<br>[29]   | Fibromyalgia<br>No specific<br>Clinical trials<br>International   | Pain<br>Tenderness<br>Fatique<br>Patient global<br>Multidimensional function<br>Sleep disturbance   | Not recommended because of lack of<br>evidence/psychometric properties of<br>corresponding measurement<br>instruments  | Yes  |  |  |  |
| COMPACT<br>[30]  | CRPS<br>No specific<br>All forms of research studies<br>International   | Pain<br>Disease severity<br>Participation and physical function<br>Emotional and psychological function<br>Self-efficacy<br>Catastrophizing<br>Patient's global impression of change  | Intensity (worst, average, least):<br>Numeric Rating Scale and PROMUS-<br>29 Profile (version 2), Neuropathic<br>components: Short-form McGill Pain<br>Questionnaire-2 (SF-MPQ2);<br>Interference: PROMIS-29 Profile<br>(version 2); Others: EQ-5D-5L<br>Severity: CRPS severity score;<br>Experience: CRPS symptoms<br>questions<br>Physical function/social participation:<br>PROMIS-29 Profile (version 2);<br>Others: EQ-5D-5L<br>Anxiety, depression, fatigue, sleep:<br>PROMIS-29 Profile (version 2);<br>Suicidal ideation: PROMIS suicidal<br>ideation question; Others: Others:<br>EQ-5D-5L<br>Pain Catastrophizing Scale<br>Pain Sale Efficancy (version 2);   |  |  |  |  |

Patient Global Impression of Change

# COS of PROs and PROMs for chronic pain trials:

#### Common PROs/ domains:

- Pain (intensity/severity)
- Physical functioning
- Some form of emotional functioning
- (Adverse Events)

#### Common PROMs:

- NRS (0-10), but....
- Physical functioning: no overlap
- Some form of emotional functioning
- (Adverse Events): no overlap

Pogatzki-Zahn et al. Curr Opin Anaesthesiol. 2019;32(5):616-622.

**Next Steps: Operationalization of PROMs?** 

Smartphone GPS signatures of patients undergoing spine surgery correlate with mobility and current gold standard outcome measures



Boaro et al,. J Neurosurg Spine. 2021;35(6):796-806..

Next steps: Alignment and acceptance of PROs and PROMs for their use in clinical trials (EMA/FDA) and real world

|                                   |       | INTEGRA                    | TE-Pair      | n Consortiı             | Jm                   |  |  |  |
|-----------------------------------|-------|----------------------------|--------------|-------------------------|----------------------|--|--|--|
|                                   |       |                            | Virtual M    | eeting                  |                      |  |  |  |
| NIH National Institutes of Health |       | June 14, 2022              |              | IMI-PainCare            |                      |  |  |  |
| HOME                              | ABOUT | SUMMER PAIN DOMAIN MEETING | REGISTRATION | CORE OUTCOME SETS (COS) | TECHNICAL ASSISTANCE |  |  |  |
| INTEGRATE-Pain Domain Meeting     |       |                            |              |                         |                      |  |  |  |

https://integrate-pain-domain-meeting.com/summer-pain-domainmeeting/

#### Thanks to ...



Hitrud Liedgens, Grünenthal



Ulrike Kaiser, Dresden Winfried Meissner, Jena



**Current Funding:** 









Bundesministerium

für Bildung

und Forschung

#### Deutsche Forschungsgemeinschaft

- sgemeinschaft
  - PO1319/3-1; (DFG Einzelantrag)
  - PO1319/4-1 (DFG-FOR2690)
  - PO1319/5-1 (DFG-FOR2690)
  - BMBF/ERaNETLac (ELAC2015/T07-0713)

POETpain (Prävention operations-bedingter

perioperativen "Transitional Pain Service")

anhaltender Schmerzen durch Einführung eines

EU/EFPIA/Innovative Medicines Initiative Joint Undertaking (IMI-PAIN-CARE); Grant #777500

- BMBF IncMeta (P-KS2019-046)
- Pog2/027/20

Part of the present presentation relates to results obtained in the Project IMI-PainCare. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No [777500]. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



# STATE OF THE ART: DIGITAL HEALTH, PAIN ASSESSMENT, AND QUALITY INDICATORS

## Winfried MEISSNER

European Pain Federation (EFIC), Department of Anaesthesiology & Intensive Care, University Hospital FSU Jena





### PROs as quality indicators and best practices from PAIN OUT

Winfried Meissner Dept. of Anesthesiology and Intensive Care Jena University Hospital



#### **Disclosures**

- Research: EU, DFG, BMBF, Pfizer, Mundipharma, Grünenthal
- Speaker / Advise: Grünenthal, Mundipharma, Ethypharm, Spectrum Therapeutics, Northern Swan, Kyowa, TAD



- A web-based quality improvement and research network addressing management of post-operative pain.
- Highly standardized assessment of PROs.
- Collaborators in Europe, Americas, Africa, South East Asia.
- Not-for-profit, academic project, coordinated from Jena University Hospital, Germany.











#### **PAIN OUT: PDCA networks**

- Mexico I & II
- France
- Ireland
- Spain
- Italy
- Belgium
- Switzerland
- Serbia | & II
- Netherlands
- China a
- China b + Pacific countries
- South Africa | & ||
- Brazil











#### **PAIN OUT: The Mexican Network**

10 Hospitals in Mexico City, 15 surgical wards.

Network leaders: Drs Ana Garduño & Victor Acosta, Salvador Zubiran Hospital







# Odd ratios of parameter differences between initial and follow-up survey





#### **Comments from Mexican colleagues:**

The staff were **<u>surprised</u>** by the results we obtained during baseline showing high levels of pain in our patients ...

... some anestheside that they were doing things very Gut feeling the example, some thought that it is unnecessar, " use epidural catheters in open abdominal surgery ...





#### Summary: Lessons learnt...

- PRO-based feedback on quality is convincing ("it's the patient's voice") and effective
- Digital tools are helpful in quality improvement efforts but personal contact remains important
- You can learn not only from the best!
- QI: not only pain intensity!
  - Functional interference
  - Intensity of pain / intensity of treatment
  - Composite Scores
  - Generic QI prefered over procedure-specific QI



#### The team:

Ruth Zaslansky





Marcus Komann

Claudia Weinmann



Philipp Baumbach



#### And many more:

J Rothaug, A Goettermann, S Mescha, Germany R Chapman, USA N Rawal, R Backstrom, Sweden D Fletcher, France M Puig, Spain R Langford, Dr K Ullrich, UK C Konrad, U Stamer, Switzerland M Schwenkglenks, Switzerland T Volk, Dr A Kopf, Germany E Pogatzki-Zahn, Germany L Fodor, Romania S Brill, Israel Y Leykin, Italy C Engel, Germany R Taylor, UK H Gerbershagen, Utrecht I Buchholtz (TAKWA), Germany

German Society of Anesthesiology (DGAI, BDA) German Society of Surgery (DGCH, BDC) AK Akutschmerz der DGSS International Pain Registry – IASP ESA, EFIC, APS Grünenthal, Pfizer, Mundipharma

> German Ministry of Health European Commission (EC)

. . .



#### **PAIN OUT: Lessons learnt**

People like it simple:

- Web access
- Graphic elements, "dash board"
- Comparison with ownself vs. with other sites
- Only few generic quality indicators but which ones?



#### PAIN OUT: Lessons learnt

Learning from each other:

- Digital exchange works but personal interaction and local leader is important!
- "Real life" data more convincing than RCTs specifically PROMs: "It's the patient's voice..."
- You can learn not only from the best!

### **Deirdre RYAN**

### President of Pain Alliance Europe (PAE)



#### **MEP Sirpa PIETIKÄINEN** (EPP, Finland)

Co-chair of the MEP Interest Group on Brain, Mind and Pain (BMP) – Video message

#### MEP Susana SOLIS PEREZ (RE, Spain)

Member of the European Parliament Special Committee on Artificial Intelligence in a Digital Age (AIDA), and Panel for the Future of Science and Technology (STOA) – *Video message* 



# PERSPECTIVES FROM THE COMMISSION, MEMBER STATES, AND STAKEHOLDERS

# Jerome DE BARROS

Policy Officer, Unit B3 – European Reference Networks and Digital Health, DG SANTE, European Commission





# **European Health Data Space**

#### Jerome de Barros, Policy Officer



# Primary and secondary uses of health data

Timely and simplified *exchange of* and *access to* health data for different use cases:

- Healthcare provision, access and control of patient over their data, (cross-border) exchange of health data;
- Digital health services (including telehealth and m-health);
- Research (eg on cancer, rare diseases, COVID-19 etc), pharmacovigilance, public health, policy making

|   |  |                                   | Legal/Governance   | Y | Quality of Data                            | Infrastructure   | Capacity building  |         |
|---|--|-----------------------------------|--|---|--|--|--|---------|
| Use of<br>health<br>data<br>(primary)   |  | Better<br>Healthcare              | Better Policy<br>Making<br>Better Research<br>and Innovation | ſ | FAIRification projects<br>Other mechanisms | Cross-border<br>infrastructure for health<br>data exchange<br>(MyHealth@EU)  | Trainings, cross-<br>border cooperation,<br>best practices, etc.<br>through different<br>funding sources<br>(EU4Health, RRF) |         |
| Re-use of<br>health data<br>(secondary) |  | Better Policy<br>Making           |  |   |  | EU-wide infrastructure<br>for secondary uses<br>(research<br>infrastructures, data<br>authorisation bodies,<br>registries) |  |         |
|   |  |                                   |  |   |  |  |  |         |
|   |  | Better Research<br>and Innovation |  |   |  |  | ( , )  |         |
|   |  |                                   |  | Ļ |  |  |  | <b></b> |



### EHDS: articulation within EU regulatory framework

Cross-border Healthcare Directive GDPR Data Governance Act AI Act Data Act MDR EHDS eIDAS Control of patients over their health data Unleash the data economy • Re-use of data for research, innovation, policy making, regulatory decisions





# What are the objectives?

Empower individuals to control their health data

Foster a single market for digital health services and products

Ensure interoperability and security of health data and a level playing field for manufacturers





Unleash the power of the health data economy





Ensure a consistent and efficient framework for the reuse of health data for research, innovation, policy-making and regulatory activities





#### Access to health data in digital format

Today, a large number of EU citizens and healthcare professionals cannot access health data in a **digital format**. Data are often available in paper, or only a limited set of data categories are available in digital format.

#### Interoperable health data



Health data is collected in such a way, that **the format is different** everywhere. This makes it impossible to understand the meaning of health data in different contexts. Therefore, interoperability standards are required to **promote wider use and portability**.

#### **Tools and infrastructure**

Member States organise health data access through different means. Some member states have patient or professional **portals** at the level of healthcare provider, region or nation, while others have apps or **personal data space** solutions. Also, registries of who should have **access** are also local, regional or national solutions. The Commission set up **MyHealth@EU infrastructure** to facilitate cross-border exchange of health data.

35

# MyHealth@EU



- Currently 10 Member States are live
- The number of connected Member States will grow rapidly in the years ahead
- Currently there are 2 services: Patient Summary and ePrescription
- This is being expanded to include Medical images, Lab results, Discharge letters, Rare disease data and other health information categories
- A Pilot will explore Patient Access to their health data in MyHealth@EU


### Primary use of health data

- The legislative proposal will focus on a number of areas:
- Expanding the rights of citizens to access and portability of health data
- Strengthening the eHealth governance
- Expanding the MyHealth@EU services
- Promoting interoperability of health software solutions (including EHR, apps, medical devices)



### Secondary use in the EHDS



Granting researchers, policy-makers and industry access to health data across borders in an interoperable, digital format



#### Access to data for research, innovation and policy making



- Creating a network of nodes as entry points into EHDS
- Nodes can be National Data Authorisation
  Bodies or European stakeholders (EMA, ECDC, Research Infrastructures)
- Rules are in place governing the access to health data (interoperability, data quality, privacy, security)
- Examples at national level are established in **Finland**, **Denmark**, **France and Norway**



### TEHDAS

- On the secondary use of health data, the Joint Action TEHDAS has also published different recommendations:
- WP5: Report on barriers to cross border data sharing and potential governance mechanisms
- WP6: Report on regulating data quality
- WP7: Report on the user journey
- WP8: Literature review on data altruism, consent and access
- Please find the reports here: <u>Results Tehdas</u>



### Secondary use of health data

- The legislative proposal will focus on a number of areas:
  - Expanding on the existing **infrastructure** in Member States (Health Data Authorisation Bodies) Introduce a European infrastructure
  - Promoting interoperability and data quality
  - Strengthening the legal base for the re-use of health data



### **Studies**

The EHDS legislative proposal is being drafted on the basis of input from:

- Public Consultation (May-July 2021)
- Study on the Assessment of rules in Member States on health data
- Study on the Interoperability of digital health systems in Member States
- Study on the use of Real World Data
- Study on regulatory gaps (to be published)
- Study on the Infrastructure options (to be published)
- Study on the Impact Assessment (to be published)

ms\_rules\_health-data\_en.pdf (europa.eu); <a href="https://ec.europa.eu/newsroom/dae/redirection/document/79897\_Digital health data and services">https://ec.europa.eu/newsroom/dae/redirection/document/79897\_Digital health data and services</a> the Europear health data space (europa.eu) Study on the use of real-world data (RWD) for research, clinical care, regulatory decision-making, health technology assessment, and policy-making - Publications Office of the EU (europa eu)

European

## Projects

EU4Health funds a number of relevant projects to further expand the European digital health infrastructure

- A pilot project to allow patients access their health data in MyHealth@EU
- Expansion of MyHealth@EU, both by allowing more Member States to establish National Contact Points and by expanding the amount of services
- A pilot project to understand the potential of a European network of National Health Data Access Bodies collaborating on secondary use of health data



### Next steps

- The next steps for the EHDS legislative proposal is to have approval from the Commission internally
- We expect the proposal to be published in the coming weeks
- If you have questions, don't hesitate to reach out: <u>Jerome.de-barros@ec.Europa.eu</u>



# Thank you



© European Union 2021

Unless otherwise noted the reuse of this presentation is authorised under the <u>CC BY 4.0</u> license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.



Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com

# PERSPECTIVES FROM THE COMMISSION, MEMBER STATES, AND STAKEHOLDERS

### **Gertrude BUTTIGIEG**

SIP Malta, and Chair of the Malta Health Network





### DIGITAL HEALTH — A PATIENT PERSPECTIVE

Gertrude A. Buttigieg (Chairperson MHN/ SIP Malta)



#### Various Digital Health Technologies





## A PATIENT PERSPECTIVE

# PLUS 1

Improved patient records through eHealth Records which bring together reports, results and other information useful for patient

ePrescriptions where used save on time & money & facilitate Cross Border Healthcare

Telemedicine facilitates access for situations where face-to-face encounters are difficult to arrange.

Telehealth infrastructure facilitates access eg in long-distance health care.

## A PATIENT PERSPECTIVE

# PLUS 2

Reliable websites & Social Media as a means of gathering information, raising awareness & finding support

Mobile health APPs assist in self-monitoring and accessing information e.g. apps for fitness, nutrition, blood–pressure/heart rate monitoring, smoking cessation etc

Wearable devises help in self-management by keeping records of temperature, glucose levels, smartphone-based pacemaker devices, pain monitoring etc.

Various ways of communication e.g. reminders allow to decrease missed appointments and saves on DNA

## A PATIENT PERSPECTIVE

MINUS

In eHealth records who 'owns' & has access to the data? What about informed consent?

ePrescriptions not working everywhere

Information over internet may be mistaken for a patient-healthcare provider encounter – may delay intervention or be damaging

Various levels of IT literacy & digital health literacy may be a disadvantage for the patients

What about data protection when using APPs? Privacy and security standards may vary from country to country – need to have models focused on value and quality of care for patients.

Different systems which code data differently give rise to interoperability issues – difficulties with COVID green pass!



#### A COLLECTION OF COMMENTS

Research Carried out in 2020 by ASLP on the experience of practitioners and clients about their experience of tele-practice gave the following comments

- Positive comments re. online sessions no effect on quality of service provision in most cases
- Technological difficulties e.g. poor internet connection
- Challenges met by elderly who might be unaccustomed to using technology
- Opportunity for indirect intervention especially for clients with poor attention maintenance and seating tolerance zoning in on the quality of parental input
- Frequency of intervention was still limited in some cases

## A PATIENT PERSPECTIVE

# INTERESTING

The quick growth of various aspects of digital health e.g. Telemedicine, personalised devices and Mobile Health apps over the past 2 years of COVID has pushed the fastforward button which will certainly not have a rewind!

Digital Health may provide a more sustainable health care in an era of growing demands and shortages of funds, time and healthcare professionals. E.g. Mental Health Services as reported by Jacqueline Sperling (Clinical Psychologist, faculty of Harvard Medical School, McLean Hospital) where online intensive group therapy for children with Anxiety and OCD were found as effective as face-to-face sessions.

Digital Innovations can help in improved

- Diagnosis
- Therapeutic/Intervention options
- Time saving & increase access for homebound persons
- Research

## A PATIENT PERSPECTIVE

FOOD FOR THOUGHT Digital era is here to stay so we have to find ways of making the best use of it – new developments such as Block Chain and Artificial Intelligence to be explored. Important that patients & carers are considered as active partners along the whole process

Recognition of the importance of Digital Health by WHO: Global Strategy on Digital Health 2020-2025.

The EU recognises the importance of Digital Health with budgets devoted to research and development of eHealth in its broadest dimensions including Digital technologies such as 5G mobile communication, artificial intelligence and supercomputing which offer new opportunities to transform the way we receive and provide health and care services. They enable innovative approaches to independent living and integrated health and social care.

Ethical issues to be considered e.g. – when medical robots are used who is responsible for mistakes, they make example in surgery, the hospital, the developer or manufacturer, the doctor who used the robot ... Who?

Digital Health implemented in a way that respects patients' choices, capacity and willingness to participate in shared decision making.



**References:** 

ASLP Malta (Nov 2021) Perspectives on online speech-language services (unpublished paper)

Bernstein C (2021) Digital Health (digital Healthcare)

<u>https://searchhealthit.techtarget.com/definition/digital-health-digital-health-digital-healthcare</u>

EPF position paper on eHealth: <u>http://www.eu-</u> <u>patient.eu/globalassets/policy/ehealth/epf-final-position-paper-on-</u> <u>ehealth 19december2016.pdf</u> WHO (2021) Global Strategy on Digital Health <u>https://apps.who.int/iris/bitstream/handle/10665/344249/97892400209</u>

24-eng.pdf

#### THANK YOU

# PERSPECTIVES FROM THE COMMISSION, MEMBER STATES, AND STAKEHOLDERS

### Andy BLEADEN Community Director, ECHAlliance





### The Global Connector for Digital Health

**European Connected Health Alliance** 

#### **Andy Bleaden**

Communities Director at ECHAlliance

- andy@echalliance.com
- oo www.echalliance.com
- @andybleaden@ECHAlliance



### **WHO**

#### **Member Organisation** (900+ organisations)

Companies, policy-makers, research orgs, health & social care providers, patient groups, insurance, procurers, government ministries



#### 20,000+ experts / professionals



#### **Not for Profit Organisation**

Registered in Ireland and in the UK



**Global reach across 78** Countries and **4.6 billion people** 

International Network of 70+ **Digital Health Ecosystems** (200+ ecosystem gatherings a year)

**WHAT** 



Connecting the dots

**Network of Geographical & Thematic Health Ecosystems** 



Comms & networking







**Events** 

**Funding**/ **Tenders** 



Global





...bring together a permanent community of stakeholders to develop a joint health agenda, aiming to address and find common solutions to regional health challenges

#### **Match Need and Solution**

The main benefit of working together in an Ecosystem is the multiplier effect of collaborating in our International Network of Ecosystems.

#### **Ecosystems:**

- break down silos,
- transform healthcare delivery,
- create economic growth



7

#### **Our International Network of Ecosystems**











#### **RESPONSES FROM THE AUDIENCE / Q&A**





15h30-15h45: Responses from the audience / Q&A

### Patrice FORGET

Chair of SIP



16h45-16h55: Synopsis and recommendations

#### HIGH-LEVEL SUMMARY FROM BREAKOUT SESSION 1 – UPTAKE OF PATIENT REPORTED OUTCOMES BY REGULATORS

- 1. Implementation of ICD-11 & ICF by all EU MS for the digitalisation of healthcare services
- 2. PROMs need to be related to the ICD-11 diagnosis/condition like disease specific PROMs (if available) and be validated
- Pain as a quality indicator assessment by the use of PROMs, e.g. pain intensity and functioning as a COS (pain is subjective) to be used in clinical trials & real life
- Patient- and clinician-friendly digital tools for health services and health
  & digital literacy participation of patients at every step



#### HIGH-LEVEL SUMMARY FROM BREAKOUT SESSION 2 – LEARNING FROM EACH OTHER AND EXCHANGING BEST PRACTICES IN DIGITAL HEALTH

 Promote the alignment of best practices for assessment and management from in-person care to digital health spaces (e.g. interdisciplinary and multimodal)

2. Establish standardised measurements throughout electronic medical recording and patient reported outcomes

**3.** Accommodate patients' expectations, assess patients' needs, plan proper and timely treatment plan to inform different stages of digital care



#### HIGH-LEVEL SUMMARY FROM BREAKOUT SESSION 3 – DIGITAL HEALTH LITERACY

- Foster the infrastructure for digital health literacy for all, including patients and HCPs, by including them in the development process of the systems, to ensure it covers their needs
- Support the training and education of HCPs and patients and organisations, in order to contribute to the continued development of digitalisation of healthcare services/systems
- **3.** Allocate adequate resources and funding for digital health literacy, to close the digital skills gap, and to address the importance of early and late learning
- 4. Ensure plain language, appropriate media, and that all materials are reviewed by patient groups





#### **Deirdre RYAN**

### President of Pain Alliance Europe (PAE)



16h55-17h00: Closure



#### An event report is available on our website:

https://www.sip-platform.eu/events/save-the-date/sip-digital-health-event-31-03-2022

#### Download our Position Paper on Digital Health:

https://www.sip-platform.eu/resources/sip-positions/digital-health-and-pain-policy

Contact details: jamie.wilkinson@efic.org


## **Contact details**

SIP PLATFORM European Pain Federation EFIC Rue de Londres 18 1050 Brussels, Belgium Phone +32 2 251 55 10

Website: <u>www.sip-platform.eu</u> Email: <u>sip@efic.org</u> SIP Project Manager: <u>Jamie.Wilkinson@efic.org</u>





The 'Societal Impact of Pain' (SIP) platform is a multi-stakeholder partnership led by the European Pain Federation EFIC and Pain Alliance Europe (PAE), which aims to raise awareness of pain and change pain policies. The scientific framework of the SIP platform is under the responsibility of EFIC and the strategic direction of the project is defined by both partners. The pharmaceutical company Grünenthal GmbH is the main sponsor of the Societal Impact of Pain (SIP) platform.



Transparency Register no. 35010244568-04